- Conditions
- Breast Cancer
- Interventions
- PD 0332991, letrozole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 51
- States / cities
- Alhambra, California • Bakersfield, California • Fullerton, California + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 618
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
- Interventions
- Docetaxel, Leucovorin, Fluorouracil, Cisplatin, Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen, Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 15
- States / cities
- Duarte, California • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
- Conditions
- Melanoma
- Interventions
- Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV, Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Obesity
- Interventions
- Phosphatidylcholine Deoxycholate, Saline
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 25 Years to 70 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Non Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage ⅢA, NSCLC Stage IIIB, NSCLC, Stage IIIA
- Interventions
- Impact® Advanced Recovery, Boost® High Protein, Radiation Therapy, Chemotherapy, Quality of life (EORTC-QLQ-30), Evaluation of Cognitive Function (FACT-Cog, v. 3.0), Mindfulness Questionnaire (FFMQ)
- Dietary Supplement · Radiation · Drug + 1 more
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
- Interventions
- Biospecimen Collection, Computed Tomography with Contrast, Magnetic Resonance Imaging, Olaparib, Quality-of-Life Assessment, Temozolomide
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 163
- States / cities
- Anchorage, Alaska • Burbank, California • Fort Lauderdale, Florida + 120 more
- Conditions
- Relapsed/ Refractory Multiple Myeloma
- Interventions
- Talquetamab, Belantamab Mafodotin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Sotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 16 more
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
- Interventions
- Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- MLTA3698A, adalimumab, leflunomide, methotrexate, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 11 more
- Conditions
- High Blood Pressure
- Interventions
- Placebo, Nebivolol
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 40 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma, Secondary Immunodeficiency
- Interventions
- IGI, 10%
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more
- Conditions
- Healthy
- Interventions
- Drug: cimetidine
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Myeloid Malignancies, Lymphoid Malignancies
- Interventions
- NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001
- Biological
- Lead sponsor
- Cristina Gasparetto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Neoplasms, Neoplasm Metastasis
- Interventions
- Vinorelbine, Investigator's choice of treatment, afatinib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 6
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 3 more
- Conditions
- Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Simple Prostatectomy, Erectile Dysfunction
- Interventions
- Cognitive-behavioral Meetings, sildenafil citrate, Vacuum Constriction Device
- Behavioral · Drug · Device
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
- Interventions
- CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
- Drug
- Lead sponsor
- Shanghai CureGene Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastasis, Breast Cancer
- Interventions
- NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Orange, California • San Francisco, California + 16 more
- Conditions
- HIV-1 Infection
- Interventions
- ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
- Conditions
- Post-operative Pain, Quadriceps Muscle Strength
- Interventions
- Adductor Canal Block, Femoral Nerve Block, Ultrasound, Stimuplex A needle, local anaesthetic injection, Steroid Drug
- Procedure · Device · Drug
- Lead sponsor
- Akron Children's Hospital
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Akron, Ohio
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Hackensack, New Jersey • Charlotte, North Carolina
- Conditions
- Heart Failure, Asymptomatic Systolic Dysfunction
- Interventions
- Nesiritide, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HIV I Infection
- Interventions
- Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
- Drug
- Lead sponsor
- Charlotte-Paige Rolle, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Opioid-use Disorder, Contraception, Neonatal Abstinence Syndrome
- Interventions
- Motivational Interviewing and Educational Training (MIET)
- Behavioral
- Lead sponsor
- Meharry Medical College
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee